KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dynavax Technologies (DVAX) Gains from Sales and Divestitures: 2012-2024

Historic Gains from Sales and Divestitures for Dynavax Technologies (DVAX) over the last 10 years, with Jun 2024 value amounting to $1.7 million.

  • Dynavax Technologies' Gains from Sales and Divestitures rose 22.66% to $1.7 million in Q2 2024 from the same period last year, while for Jun 2024 it was $1.7 million, marking a year-over-year increase of 22.66%. This contributed to the annual value of $1.5 million for FY2023, which is 26.78% up from last year.
  • As of Q2 2024, Dynavax Technologies' Gains from Sales and Divestitures stood at $1.7 million, which was up 6.48% from $1.6 million recorded in Q1 2024.
  • Dynavax Technologies' 5-year Gains from Sales and Divestitures high stood at $1.7 million for Q2 2024, and its period low was $533,000 during Q1 2021.
  • Its 3-year average for Gains from Sales and Divestitures is $1.3 million, with a median of $1.3 million in 2023.
  • As far as peak fluctuations go, Dynavax Technologies' Gains from Sales and Divestitures crashed by 52.85% in 2021, and later soared by 122.53% in 2022.
  • Dynavax Technologies' Gains from Sales and Divestitures (Quarterly) stood at $1.1 million in 2020, then slumped by 52.85% to $537,000 in 2021, then skyrocketed by 122.53% to $1.2 million in 2022, then grew by 26.78% to $1.5 million in 2023, then increased by 22.66% to $1.7 million in 2024.
  • Its Gains from Sales and Divestitures stands at $1.7 million for Q2 2024, versus $1.6 million for Q1 2024 and $1.5 million for Q4 2023.